A Study of Tirzepatide (LY3298176) in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Overweight (SURMOUNT-CN)
(SURMOUNT-CN Trial)

Recruiting in Palo Alto (17 mi)

+34 other locations

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 3

Waitlist Available

Sponsor: Eli Lilly and Company

Pivotal Trial (Near Approval)

Prior Safety Data

Approved in 6 jurisdictions

Trial Summary

What is the purpose of this trial?This is a study of tirzepatide in Chinese participants without Type 2 Diabetes who have obesity or overweight. The main purpose is to learn more about how tirzepatide affects body weight.

Eligibility Criteria

Inclusion Criteria

Have a BMI ≥28 kilogram/square meter (kg/m²), or ≥24 kg/m² and previous diagnosis with at least one of the following comorbidities: hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease

Have a history of at least one self-reported unsuccessful dietary effort to lose body weight

Participant Groups

3Treatment groups

Experimental Treatment

Placebo Group

Group I: 15 mg TirzepatideExperimental Treatment1 Intervention

Participants received maintenance dose 15 mg with dose escalation starting from 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and then 15 mg tirzepatide administered SC QW.

Group II: 10 Milligrams (mg) TirzepatideExperimental Treatment1 Intervention

Participants received maintenance dose 10 mg with dose escalation starting from 2.5 mg, 5 mg, 7.5 mg, and then 10 mg tirzepatide administered subcutaneously (SC) once weekly (QW).

Group III: PlaceboPlacebo Group1 Intervention

Participants received matching placebo SC QW.

Tirzepatide is already approved in United States, European Union, Canada, Australia, United States, United Kingdom for the following indications:

🇺🇸 Approved in United States as Mounjaro for: